As director of reimbursement strategy, Rob leads market access and evidence development activities for Thermo Fisher Scientific’s clinical sequencing division. Experienced in all facets of NGS testing’s coverage, coding, and billing – Rob works with CLIA labs, pharma partners and coalitions to explain the complex and often contradictory U.S. environment and devise pathways to achieve their desired goals. He’s also worked with Oncomine™ Dx Target Test: the first FDA-approved next-generation sequencing (NGS) in vitro diagnostic test for non-small cell lung cancer. This companion diagnostic is now covered nationally by Medicare and dozens of commercial payers. Rob joined Thermo Fisher (Life Technologies) in 2012 through an acquisition of Navigenics, where he led development and growth of payers and employers. Rob was also a Territory Vice President at RelayHealth, with duties that included payer-facing sales of secure messaging and e-prescribing. He also held senior sales and sales management positions with UnitedHealthcare.